Osteoboost Health Launches FDA-Cleared Prescription Wearable Device for Low Bone Density, Filling Critical Treatment Gap for 60M+ Americans
- First-ever drug-free prescription solution to treat low bone density
- Class II FDA-cleared De Novo, Breakthrough Device for postmenopausal women with osteopenia
- Patented vibration therapy targets spine and hips, areas at highest risk of fractures
- Over 1000 unique physicians prescribed during the pre-order phase
- New investments from AARP, Harvard Business School Angels, and Esplanade Ventures
Redwood City, CA, May 7, 2025 – Osteoboost Health, Inc today announced the nationwide availability of Osteoboost, the first and only FDA-cleared prescription medical device for low bone density. Osteoboost represents a novel, protective and preventative approach to bone health at a time when tens of millions are left without effective options.
As new generations reach menopause and retirement, the idea of “aging gracefully” is evolving into a vision of longevity centered on strength and an active lifestyle. Bone health is pivotal to this shift. Osteoboost offers hope to millions with low bone density, helping reduce fracture risk that threatens mobility and independence.
Osteoboost is a brand-new wearable that bridges the gap between next-generation consumer health technology and rigorously tested medical innovation. Designed for effortless, at-home use, this clinically proven device delivers targeted vibration therapy directly to the spine and hips: areas at high risk for osteoporotic fractures. More than just a consumer-friendly wearable, Osteoboost is an FDA-cleared medical device, designated a Breakthrough Device by the FDA and approved through the De Novo pathway. Its patented vibration technology, precisely calibrated for bone health, was clinically validated in a gold-standard randomized controlled trial to significantly slow the loss of vertebral bone density and strength.
While osteoporosis often receives the most attention, over half of all fragility fractures happen during osteopenia, the precursor to osteoporosis. In the United States, 54% of postmenopausal women are osteopenic. Until now, treatments have focused on medications typically only prescribed in the osteoporosis stage and usually not offered until after a bone fracture.
Leading Osteoboost is CEO Laura Yecies, a seasoned entrepreneur with over 30 years of building and scaling companies, including selling her prior startup to Apple.
“The longevity conversation is everywhere, but people rarely mention bone health even though it is fundamental to aging with confidence,” said Yecies. “Osteoboost empowers people to lead longer, stronger, and more active lives. And while the belt is sophisticated medical technology rigorously tested and validated for efficacy, the treatment is so easy – 30 minutes a day of gentle vibration therapy that can be done while walking, cooking, or other daily activities.”
A gold-standard, double-blinded, placebo-controlled clinical trial at the University of Nebraska Medical Center demonstrated that Osteoboost slowed bone density and strength loss in postmenopausal women with osteopenia who used it at least 3 times per week:
- 85% reduction in the loss of bone density in the spine
- 83% reduction in the loss of bone strength in the spine
- 55% reduction in the loss of bone density in the hip
Before today’s launch, over 1,000 physicians, including those at 30+ leading academic medical centers, had already prescribed Osteoboost—highlighting both patient demand and the vast treatment gap.
- More women will suffer an osteoporotic fracture than experience a heart attack, stroke, and breast cancer combined.
- Osteoporotic fractures cost the U.S. healthcare system $46 billion annually.
- Calcium, vitamin D, and exercise alone are often not enough to prevent bone loss in high-risk individuals.
“It’s been a long time since we’ve seen any new innovation for bone health, and yet every day I see patients who are terrified of the risks they face just walking down the street,” said Dr. Yevgeniya Kushchaeva, Clinical Director of University of South Florida Health Adult Endocrinology, and Medical Director of Adult Osteoporosis Program.“Osteoboost did this the right way. They spent years investing in the clinical trial and FDA approval processes – not an easy feat even for larger pharmaceutical companies.”
Kushchaeva continued, “The fact that the trial showed such strong results, and had no serious adverse events from the device, plus had over 80% patient compliance, all inspires tremendous confidence. My patients are already asking me about this, I’m actively prescribing it, and I’m looking forward to seeing their results.”
To increase accessibility, the company is offering online prescription consultations through its partnership with Beluga Health. Patients now have the flexibility to obtain a prescription through their personal physician or opt for the convenience of online prescribing from home. This streamlined process removes delays, making it easier and faster for individuals to access new treatments and take proactive steps toward improving their bone health.
The company also announced new strategic investments from AARP, Harvard Business School Angels, and She’s Independent, plus a follow-on investment from Esplanade Healthtech Ventures.
Osteoboost recently secured its sixth U.S. patent, further strengthening its intellectual property portfolio and leadership in vibration technology. Last July, Osteoboost Health acquired Wellen, an online exercise and fall prevention platform designed for women with low bone density.
About Osteoboost Health, Inc.
Osteoboost Health is a Redwood City-based medical technology company developing innovative, non-invasive, and science-backed solutions for people with low bone density. Osteoboost is backed by leading investors, including Esplanade Ventures, Terumo Medical Corporation, Ambit Health Ventures, Portfolia, Astia Angels, and Golden Seeds. For more information, including the Instructions for Use, please visit https://osteoboost.com/.
Media Contact
VSC for Osteoboost
osteoboost@vsc.co